REVIV Emerges as a Provider of Biotech-Enabled Health Solutions After Eight Years Building the Intelligence Layer for Human Health

Manchester, UK - May 18, 2026 - 
REVIV, historically known as a global leader in IV therapy, today announced its evolution into a provider of biotech-enabled health solutions, revealing an eight-year transformation focused on building the life science, data and technology infrastructure required to personalize health decisions at scale.

While REVIV has delivered more than 3 million clinical interventions across 40+ countries, that visible footprint represents only part of the company’s story.

Behind the scenes, REVIV has been building a technology enabled ecosystem designed to answer one of the most important challenges in modern health:

How do you translate human biology into precise, actionable decisions at scale?

Over the past decade, IV therapy has served as more than a treatment category for REVIV. It has created a controlled clinical environment where the company could directly observe how people respond to nutritional inputs, clinical protocols and personalized interventions.

Through this environment, REVIV has been able to:

            •           Test and validate interventions in real-world settings

            •           Measure physiological response across diverse populations

            •           Build datasets connecting biology, intervention and outcome

            •           Develop clinical protocols informed by real-world evidence

This foundation has enabled REVIV to move beyond traditional wellness delivery and into applied human life science.

The result is a continuously evolving intelligence layer built from real-world human data, clinical experience and measurable outcomes.

Over the past eight years, REVIV, supported by its strategic partners, has invested more than $70 million into developing the infrastructure behind this shift, including:

            •           Proprietary life science frameworks

            •           Biological data mapping across individuals

            •           Integrated diagnostic and intervention pathways

            •           Technology platforms designed to support personalized protocols

            •           A continuously learning intelligence engine

This work has largely taken place outside of public view.

Not to build another health product, but to build the system that determines which health products, protocols and interventions should be used, when they should be used, and for whom.

For a detailed overview of REVIV's evolution and the development of it's platform, visit: http://www.revivglobal.com.

Global health and wellness spend continues to rise, yet remains highly fragmented.

Consumers and patients are spending billions across supplements, diagnostics, therapies, aesthetics, longevity solutions and clinical services. Too often, these decisions are driven by trends, influencers, generic protocols and disconnected advice.

What has been missing is a decision infrastructure capable of translating individual biology into structured, personalized action.

 REVIV has built that infrastructure.

By mapping biological, lifestyle and intervention data at scale, REVIV is now positioned to:

            •           Translate individual biology into structured decision frameworks

            •           Define which interventions are most relevant for each individual

            •           Connect diagnostics, nutrition, therapies and clinical care into one pathway

            •           Continuously adapt recommendations based on measurable outcomes

This creates a new layer within the health economy:

A decision infrastructure that sits between biology and spend.

As part of its next phase, REVIV will power the launch of MyIOS Health, a B2C and B2B technology enabled ecosystem expected to go live later this year through its joint venture with Cardone Ventures and 10X Health.

Launching under the 10XREVIV partnership, MyIOS Health will translate an individuals biological data into a real-time Operating System Score and define a precise health protocol covering diagnostics, nutrition, therapies and clinical care. Not only redirecting their former unstructured spend into a full science backed suite of product recommendations, but also connecting them into a global network of clinics offering the latest in cutting edge clinical interventions.

While MyIOS Health has not yet been publicly released, it represents the first large-scale deployment of the infrastructure REVIV has spent nearly a decade building.

Sarah Lomas, CEO and Co-Founder of REVIV, said:

“For years, the market has seen REVIV as an IV therapy company. In reality, we have been building something much bigger.

 IV therapy gave us a controlled environment to test, validate and understand human biology in real time. That foundation has enabled us to build an intelligence layer capable of guiding health decisions at scale.

We are now stepping out of stealth as a biotech-enabled health platform at a time when the world is ready to move from guesswork to precision.”

As global demand for personalized, data-driven health accelerates, REVIV is entering a new phase focused on scaling its technologies across key international markets, activating its partner ecosystem and preparing for the public launch of MyIOS Health.

The company is currently engaging with a select group of strategic investors to support this next stage of growth.

 ENDS

REVIV Global is a provider of biotech-enabled health solutions that has delivered more than 3 million clinical interventions across 40+ countries. Over the past eight years, REVIV has built proprietary life science, data and technology infrastructure designed to translate human biology into structured, scalable health decisions.

MyIOS Health is an upcoming B2C & B2B technology enabled precision health ecosystem. Powered by REVIV’s intelligence layer, it will translate an individuals biological data into an Operating System Score and deliver personalized, data-driven health protocols. The platform is expected to launch later this year through the 10XREVIV joint venture.

press@revivme.com